On the other hand, the immunosuppressive properties of SEMA3A may account for situations where high amounts of SEMA3A are associated with poor prognosis in urothelial cancer25, glioblastoma multiforme26, and hepatocellular carcinoma (HCC)27. This evidence concerns the gene SEMA3A and hepatocellular carcinoma.